<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLINDAMYCIN PHOSPHATE - clindamycin phosphate cream </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>CLINDAMYCIN PHOSPHATE VAGINAL CREAM USP, 2%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">FOR INTRAVAGINAL USE ONLY<br>NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl- <span class="Italics">trans</span>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<span class="Italics">threo</span>-α-<span class="Italics">D-galacto</span>-octopyranoside 2-(dihydrogen phosphate). It has a molecular weight of 504.96, and the molecular formula is C<span class="Sub">18</span>H<span class="Sub">34</span>ClN<span class="Sub">2</span>O<span class="Sub">8</span> PS. The structural formula is represented below:</p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9&amp;name=clindamycin-phosphate-vaginal-cream-01.jpg">
</div>
<p>Clindamycin phosphate vaginal cream 2%, is a semi-solid, white cream, which contains 2% clindamycin phosphate, USP, at a concentration equivalent to 20 mg clindamycin per gram. The pH of the cream is between 3.0 and 6.0. The cream also contains benzyl alcohol, cetostearyl alcohol, cetyl palmitate, mineral oil, polysorbate 60, propylene glycol, sorbitan monostearate, and stearic acid.</p>
<p>Each applicatorful of 5 grams of vaginal cream contains approximately 100 mg of clindamycin phosphate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Following a once a day intravaginal dose of 100 mg of clindamycin phosphate vaginal cream 2%, administered to 6 healthy female volunteers for 7 days, approximately 5% (range 0.6% to 11%) of the administered dose was absorbed systemically. The peak serum clindamycin concentration observed on the first day averaged 18 ng/mL (range 4 to 47 ng/mL) and on day 7 it averaged 25 ng/mL (range 6 to 61 ng/mL). These peak concentrations were attained approximately 10 hours post-dosing (range 4-24 hours).</p>
<p>Following a once a day intravaginal dose of 100 mg of clindamycin phosphate vaginal cream 2%, administered for 7 consecutive days to 5 women with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>, absorption was slower and less variable than that observed in healthy females. Approximately 5% (range 2% to 8%) of the dose was absorbed systemically. The peak serum clindamycin concentration observed on the first day averaged 13 ng/mL (range 6 to 34 ng/mL) and on day 7 it averaged 16 ng/mL (range 7 to 26 ng/mL). These peak concentrations were attained approximately 14 hours post-dosing (range 4-24 hours).</p>
<p>There was little or no systemic accumulation of clindamycin after repeated vaginal dosing of clindamycin phosphate vaginal cream 2%. The systemic half-life was 1.5 to 2.6 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>MICROBIOLOGY</h1>
<p class="First">Clindamycin inhibits bacterial protein synthesis at the level of the bacterial ribosome. The antibiotic binds preferentially to the 50S ribosomal subunit and affects the process of peptide chain initiation. Although clindamycin phosphate is inactive <span class="Italics">in vitro</span>, rapid <span class="Italics">in vivo</span> hydrolysis converts this compound to the antibacterially active clindamycin.</p>
<p>Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>. (See <a href="#s6">INDICATIONS AND USAGE.</a>) Standard methodology for the susceptibility testing of the potential <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> pathogens, <span class="Italics">Gardnerella vaginalis, Mobiluncus</span> spp., or <span class="Italics">Mycoplasma hominis</span>, has not been defined. Nonetheless, clindamycin is an antimicrobial agent active <span class="Italics">in vitro</span> against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms that have been reported to be associated with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>:</p>
<a name="ie5316fd6-e233-4264-875b-18061b989666"></a><table width="100%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="Italics">Bacteroides spp.</span></td>
<td align="center" valign="top"><span class="Italics">Mycoplasma hominis</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Italics">Peptostreptococcus spp.</span></td>
<td align="center" valign="top"><span class="Italics">Gardnerella vaginalis</span></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="Italics">Mobiluncus spp.</span></td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> (formerly referred to as <span class="Italics">Haemophilus</span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Gardnerella</span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, nonspecific <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Corynebacterium</span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See <a href="#s27">CLINICAL STUDIES.</a>)</p>
<p><span class="Bold">NOTE:</span> For purposes of this indication, a clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> is usually defined by the presence of a homogeneous <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> include (a) markedly reduced or absent <span class="Italics">Lactobacillus</span> morphology, (b) predominance of <span class="Italics">Gardnerella</span> morphotype, and (c) absent or few white blood cells.</p>
<p>Other pathogens commonly associated with <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>, e.g., <span class="Italics">Trichomonas vaginalis</span>, <span class="Italics">Chlamydia trachomatis, N. gonorrhoeae, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span>, and <span class="Italics">Herpes simplex</span> virus should be ruled out.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Clindamycin phosphate vaginal cream 2%, is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clindamycin, lincomycin, or any of the components of this vaginal cream. Clindamycin phosphate vaginal cream 2%, is also contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span>, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or a history of "antibiotic-associated" <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Orally and parenterally administered clindamycin has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> which may end fatally. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported with the use of orally and parenterally administered clindamycin, as well as with topical (dermal) formulations of clindamycin. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of clindamycin, even when administered by the vaginal route, because approximately 5% of the clindamycin dose is systemically absorbed from the vagina.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile</span> is a primary cause of "antibiotic-associated′′ <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <span class="Italics">Clostridium difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antimicrobial treatment.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s10"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Clindamycin phosphate vaginal cream 2%, contains ingredients that will cause burning and irritation of the eye. In the event of accidental contact with the eye, rinse the eye with copious amounts of cool tap water.</p>
<p>The use of clindamycin phosphate vaginal cream 2% may result in the overgrowth of nonsusceptible organisms in the vagina. In clinical studies involving 600 non-pregnant women who received treatment for 3 days, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> was detected, either symptomatically or by culture, in 8.8% of patients. In 9% of the patients, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> was recorded. In clinical studies involving 1325 non-pregnant women who received treatment for 7 days, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> was detected, either symptomatically or by culture, in 10.5% of patients. <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> was recorded in 10.7% of the patients. In 180 pregnant women who received treatment for 7 days, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> was detected, either symptomatically or by culture, in 13.3% of patients. In 7.2% of the patients, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> was recorded. <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans, as reported here, includes the terms: <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal moniliasis</span> and <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> (body as a whole). <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> includes the terms: vulvo-vaginal disorder, <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>, <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, <span class="product-label-link" type="condition" conceptid="194871" conceptname="Trichomonal vulvovaginitis">trichomonal vaginitis</span>, and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s11"></a><a name="section-8.2"></a><p></p>
<h2>Information for the Patient:</h2>
<p class="First">The patient should be instructed not to engage in vaginal intercourse, or use other vaginal products (such as tampons or douches) during treatment with this product.</p>
<p><span class="Bold">The patient should also be advised that this cream contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, use of such products within 72 hours following treatment with clindamycin phosphate vaginal cream 2%, is not recommended.</span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s12"></a><a name="section-8.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s13"></a><a name="section-8.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames test. Both tests were negative. Fertility studies in rats treated orally with up to 300 mg/kg/day (31 times the human exposure based on mg/m<span class="Sup">2</span> ) revealed no effects on fertility or mating ability.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="s14"></a><a name="section-8.5"></a><p></p>
<h2>Pregnancy: Teratogenic effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-8.5.1"></a><p></p>
<h3>Pregnancy Category B</h3>
<p class="First">There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. This drug should be used during the first trimester of pregnancy only if clearly needed.</p>
<p>Clindamycin phosphate vaginal cream 2% has been studied in pregnant women during the second trimester. In women treated for seven days, <span class="product-label-link" type="condition" conceptid="437342" conceptname="Abnormality of forces of labor">abnormal labor</span> was reported in 1.1% of patients who received clindamycin vaginal cream 2% compared with 0.5% of patients who received placebo.</p>
<p>Reproduction studies have been performed in rats and mice using oral and parenteral doses of clindamycin up to 600 mg/kg/day (62 and 25 times, respectively, the maximum human exposure based on mg/m<span class="Sup">2</span> ) and have revealed no evidence of harm to the fetus due to clindamycin. In one mouse <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> were observed in treated fetuses; this outcome was not produced in other mouse <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> or in other species and is, therefore, considered to be a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> specific effect.</p>
<p>See <a href="#s6">INDICATIONS AND USAGE</a>; <a href="#s10">PRECAUTIONS, General</a>; and <a href="#s19">ADVERSE REACTIONS</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s16"></a><a name="section-8.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Clindamycin has been detected in human milk after oral or parenteral administration. It is not known if clindamycin is excreted in human milk following the use of vaginally administered clindamycin phosphate.</p>
<p>Because of the potential for serious adverse reactions in nursing infants from clindamycin phosphate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s17"></a><a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s18"></a><a name="section-8.8"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies for clindamycin phosphate vaginal cream 2% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s19"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-9.1"></a><p></p>
<h2>Clinical trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-9.1.1"></a><p></p>
<p class="First"><span class="Bold">Non-pregnant Women</span>: In clinical trials involving non-pregnant women, 1.8% of 600 patients who received treatment with clindamycin phosphate vaginal cream 2% for 3 days and 2.7% of 1325 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered clindamycin phosphate vaginal cream 2%, were reported for 20.7% of the patients receiving treatment for 3 days and 21.3% of the patients receiving treatment for 7 days. Events occurring in ≥1% of patients receiving clindamycin phosphate vaginal cream 2% are shown in <a href="#f2">Table 1</a>.</p>
<div class="Figure">
<a name="f2"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9&amp;name=clindamycin-phosphate-vaginal-cream-02.jpg"><p class="MultiMediaCaption">Events Occuring in ≥ 1% of Non-pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2%</p>
</div>
<p>Other events occurring in &lt;1% of the clindamycin vaginal cream 2% groups include:</p>
<p><span class="Italics">Urogenital system</span>: <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>/<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>, and <span class="product-label-link" type="condition" conceptid="4244072" conceptname="Vaginal pain">vaginal pain</span>.</p>
<p><span class="Italics">Body as a whole:</span> localized <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, generalized <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">halitosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory swelling</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>.</p>
<p><span class="Italics">Digestive system:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>.</p>
<p><span class="Italics">Endocrine system</span>: <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>.</p>
<p><span class="Italics">Central nervous system:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Italics">Respiratory system:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (non-application site), <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Special senses:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-9.1.2"></a><p></p>
<p class="First"><span class="Bold">Pregnant Women</span>: In a clinical trial involving pregnant women during the second trimester, 1.7% of 180 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered clindamycin phosphate vaginal cream 2%, were reported for 22.8% of pregnant patients. Events occurring in ≥1% of patients receiving either clindamycin phosphate vaginal cream 2% or placebo are shown in <a href="#f3">Table 2</a>.</p>
<div class="Figure">
<a name="f3"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9&amp;name=clindamycin-phosphate-vaginal-cream-03.jpg"><p class="MultiMediaCaption">Events Occuring in ≥ 1% of Pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2% or Placebo</p>
</div>
<p>Other events occurring in &lt;1% of the clindamycin vaginal cream 2% group include:</p>
<p><span class="Italics">Urogenital system:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="4244072" conceptname="Vaginal pain">vaginal pain</span>, and <span class="product-label-link" type="condition" conceptid="194871" conceptname="Trichomonal vulvovaginitis">trichomonal vaginitis</span>.</p>
<p><span class="Italics">Body as a whole:</span> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>.</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (topical application site) and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-9.1.3"></a><p></p>
<h3>Other clindamycin formulations:</h3>
<p class="First">Clindamycin vaginal cream affords minimal peak serum levels and systemic exposure (AUCs) of clindamycin compared to 100 mg oral clindamycin dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral clindamycin, the possibility of these and other reactions cannot be excluded presently. Data from well-controlled trials directly comparing clindamycin administered orally to clindamycin administered vaginally are not available.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="e23"></a><a name="section-9.1.3.1"></a><p></p>
<p class="First">The following adverse reactions and altered laboratory tests have been reported with the <span class="Bold">oral or parenteral</span> use of clindamycin:</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (See <a href="#s8">WARNINGS.</a>)</p>
<p><span class="Italics">Hematopoietic:</span> Transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>), <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have been reported. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of these reports.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span>: <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">Maculopapular rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been observed during drug therapy. Generalized mild to moderate morbilliform-like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> are the most frequently reported of all adverse reactions. Rare instances of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, some resembling <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, have been associated with clindamycin. A few cases of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported. If a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> occurs, the drug should be discontinued.</p>
<p><span class="Italics">Liver:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and abnormalities in liver function tests have been observed during clindamycin therapy.</p>
<p><span class="Italics">Musculoskeletal</span>: Rare instances of <span class="product-label-link" type="condition" conceptid="4025831" conceptname="Arthritis mutilans">polyarthritis</span> have been reported.</p>
<p><span class="Italics">Renal:</span> Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and/or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> has been observed in rare instances.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s24"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Vaginally applied clindamycin phosphate vaginal cream 2% could be absorbed in sufficient amounts to produce systemic effects. (See <a href="#s8">WARNINGS.</a>)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s25"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one applicatorful of clindamycin phosphate vaginal cream 2%, (5 grams containing approximately 100 mg of clindamycin phosphate) intravaginally, preferably at bedtime, for 3 or 7 consecutive days in non-pregnant patients and for 7 consecutive days in pregnant patients. (See <a href="#s27">CLINICAL STUDIES.</a>)</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s26"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Clindamycin Phosphate Vaginal Cream 2% (clindamycin phosphate vaginal cream) is a white to off-white cream having a slight odor and is supplied as follows:</p>
<p>40 g tube (with 7 disposable applicators)  NDC 54868-5307-0</p>
<p>Store at 20° to 25°C (68° to 77° F)[see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s27"></a><a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In two clinical studies involving 674 evaluable non-pregnant 
women with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> comparing clindamycin phosphate vaginal cream 2% 
for 3 or 7 days, the clinical cure rates, determined at 1 month posttherapy, 
ranged from 72% to 81% for the 3-day treatment and 84% to 86% for the 7-day 
treatment.</p>
<a name="ia5befe9c-ae38-449c-82ab-01a1b45e4fde"></a><table width="100%">
<col align="left" width="20%">
<col align="left" width="20%">
<col align="left" width="20%">
<col align="left" width="20%">
<col align="left" width="20%">
<tbody class="Headless">
<tr class="First">
<td align="left"><br></td>
<td align="left"><span class="Underline">Clindamycin 
Phosphate 3 Day</span></td>
<td align="left"><span class="Underline">Clindamycin 
Phosphate 7 Day</span></td>
</tr>
<tr>
<td align="left">U.S. Study</td>
<td align="left">94/131</td>
<td align="left">72%</td>
<td align="left">110/128</td>
<td align="left">86%</td>
</tr>
<tr class="Last">
<td align="left">European Study</td>
<td align="left">161/199</td>
<td align="left">81%</td>
<td align="left">181/216</td>
<td align="left">84%</td>
</tr>
</tbody>
</table>
<p>In a clinical study involving 249 evaluable pregnant patients in the second 
and third trimester treated for 7 days, the clinical cure rate, determined at 1 
month posttherapy, was 60% (77/129) in the clindamycin arm and 9% (11/120) for 
the vehicle arm. The determination of clinical cure was based on the absence of 
a "fishy" amine odor when the <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> was mixed with a 10% KOH 
solution and the absence of clue cells on microscopic examination.</p>
<p>E. FOUGERA &amp; CO.<br>A division of Nycomed US Inc.<br>Melville, New York 
11747</p>
<p>I2277<br>R4/08<br>#116</p>
<br><p><span class="Bold">Relabeling of "Additional Barcode Label" by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s28"></a><a name="section-14"></a><p></p>
<h1>DIRECTIONS FOR USE</h1>
<p class="First">7 Disposable plastic applicators are provided with this package. They are designed to allow proper vaginal administration of the cream.</p>
<p>Remove cap from cream tube. Screw a plastic applicator on the threaded end of the tube.</p>
<p>Rolling tube from the bottom, squeeze gently and force the medication into the applicator.</p>
<p>The applicator is filled when the plunger reaches its predetermined stopping point.</p>
<p>Unscrew the applicator from the tube and replace the cap.</p>
<div class="Figure">
<a name="f4"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9&amp;name=clindamycin-phosphate-vaginal-cream-04.jpg">
</div>
<p>While lying on your back, firmly grasp the applicator barrel and insert into vagina as far as possible without causing <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>.</p>
<p>Slowly push the plunger until it stops. Carefully withdraw applicator from vagina, and discard applicator.</p>
<div class="Figure">
<a name="f5"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9&amp;name=clindamycin-phosphate-vaginal-cream-05.jpg">
</div>
<p><span class="Sub">REMEMBER TO APPLY ONE APPLICATORFUL EACH NIGHT BEFORE BEDTIME, OR AS PRESCRIBED BY YOUR DOCTOR.</span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="e90"></a><a name="section-15"></a><p></p>
<h1>INSTRUCCIONES PARA LA PACIENTE</h1>
<p class="First">Este envase contiene 7 aplicadores de plástico desechables. Los aplicadores están diseñados para la adminstración apropiada de la crema en la vagina.</p>
<p>Remueva la tapa del tubo de crema y enrosque el aplicador de plástico al tubo.</p>
<p>Exprima el tubo suavemente desde el extremo inferior y fuerce el medicamento al aplicador.</p>
<p>El aplicador estará lleno cuando el émbolo llega a su máxima longitud. Desenrosque el aplicador del tubo y vuelva a poner la tapa.</p>
<div class="Figure">
<a name="f6"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9&amp;name=clindamycin-phosphate-vaginal-cream-06.jpg">
</div>
<p>Acuéstese de espada y agarrando firemente el aplicador, introdúzcalo en la vagina tanto como sea posible sin causar molestias.</p>
<p>Empuje lentamente el émbolo hasta que se detenga.</p>
<p>Saque el aplicador cuidadosamente de la vagina y descártelo.</p>
<div class="Figure">
<a name="f7"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9&amp;name=clindamycin-phosphate-vaginal-cream-07.jpg">
</div>
<p>RECUERDE APLICARSE UN APLICADOR LLENO TODAS LAS NOCHES AL ACOSTARSE, O DE ACUDERDO CON LAS INDICACIONES DE SU MEDICO.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s30"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 40 
GRAM CARTON </span></p>
<p><span class="Bold">CLINDAMYCIN<br>PHOSPHATE<br>VAGINAL CREAM<br>USP, 
2%<br></span>equivalent to 2% clindamycin </p>
<p>For Intravaginal Use Only.<br>Not for Ophthalmic,<br>Dermal, or Oral Use. 
</p>
<p>Rx only </p>
<p><span class="Bold">NET WT 40 grams<br></span>with<br>7 applicators</p>
<p><img alt="40 GRAM CARTON" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=706dd0b6-367c-4950-88fe-7a6c0661c2b9&amp;name=cream%20package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLINDAMYCIN PHOSPHATE 		
					</strong><br><span class="contentTableReg">clindamycin phosphate cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5307(NDC:0168-0277)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLINDAMYCIN PHOSPHATE</strong> (CLINDAMYCIN) </td>
<td class="formItem">CLINDAMYCIN PHOSPHATE</td>
<td class="formItem">20 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETOSTEARYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CETYL PALMITATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 60</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITAN MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5307-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">40 g in 1 TUBE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065139</td>
<td class="formItem">05/19/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>580d387f-c4ba-4a04-b664-8b93aa6fe483</div>
<div>Set id: 706dd0b6-367c-4950-88fe-7a6c0661c2b9</div>
<div>Version: 1</div>
<div>Effective Time: 20090831</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
